Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
27 01 2020
Historique:
entrez: 28 1 2020
pubmed: 28 1 2020
medline: 16 7 2020
Statut: epublish

Résumé

Neisseria meningitidis, a gram-negative diplococcus, is typically an asymptomatic coloniser of the oropharynx and nasopharynx. Passage of N. meningitidis into the bloodstream can cause invasive meningococcal disease (IMD), a potentially life-threatening illness with rapid onset that generally presents as meningitis, septicemia or both. Serogroup W IMD has been increasing in prevalence in recent years, and observations suggest that it may present with atypical signs and symptoms. Herein, a literature search was performed to identify trends in atypical serogroup W IMD presentation in order to review those that are most prevalent. Findings indicate that the most prevalent atypical presentations of serogroup W IMD include acute gastrointestinal (GI) symptoms, septic arthritis and bacteremic pneumonia or severe upper respiratory tract infection, notably epiglottitis. Atypical clinical presentation is associated with higher case fatality rates and can lead to misdiagnoses. Such risks highlight the need for clinicians to consider IMD in their differential diagnoses of patients with acute GI symptoms, septic arthritis or bacteremic pneumonia, primarily in regions where serogroup W is prevalent.

Identifiants

pubmed: 31983356
doi: 10.1017/S0950268819002152
pii: S0950268819002152
pmc: PMC7019474
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12

Références

Can Commun Dis Rep. 2017 Jul 06;43(7-8):144-149
pubmed: 29770081
Euro Surveill. 2015 Jul 16;20(28):
pubmed: 26212140
Pediatr Infect Dis J. 2008 Mar;27(3):193-9
pubmed: 18277925
Lancet Public Health. 2017 Oct;2(10):e473-e482
pubmed: 29253430
Clin Infect Dis. 2018 Sep 28;67(8):1220-1227
pubmed: 29608658
Emerg Infect Dis. 2017 Jul;23(7):1070-1078
pubmed: 28628448
Travel Med Infect Dis. 2003 Feb;1(1):19-28
pubmed: 17291877
Ned Tijdschr Geneeskd. 2017;161:D1456
pubmed: 28745253
Euro Surveill. 2004 Nov;9(11):37-9
pubmed: 15591689
Am Rev Respir Dis. 1982 Feb;125(2):255-7
pubmed: 6802047
Scand J Infect Dis. 1984;16(3):247-54
pubmed: 6436962
J Infect. 2018 Feb;76(2):149-158
pubmed: 29132919
Int Health. 2016 Nov;8(6):369-371
pubmed: 27620924
BMC Infect Dis. 2006 Jan 19;6:7
pubmed: 16420709
PLoS One. 2018 Mar 8;13(3):e0193572
pubmed: 29518095
JAMA. 1981 Nov 6;246(18):2060-1
pubmed: 6793741
Am J Med. 2018 Jan;131(1):37-40
pubmed: 28821376
Clin Infect Dis. 2004 Jun 1;38(11):1638-9
pubmed: 15156455
Asian Pac J Trop Med. 2017 Nov;10(11):1019-1029
pubmed: 29203096
Euro Surveill. 2012 Nov 01;17(44):
pubmed: 23137486
Mikrobiyol Bul. 2010 Jul;44(3):473-8
pubmed: 21063998
Epidemiol Infect. 2010 Jul;138(7):976-8
pubmed: 19845997
Vaccine. 2012 May 30;30 Suppl 2:B3-9
pubmed: 22607896
Commun Dis Intell Q Rep. 2016 Dec 24;40(4):E454-E459
pubmed: 28043219
Ugeskr Laeger. 2018 Apr 16;180(16):
pubmed: 29690994
Ugeskr Laeger. 2017 Nov 27;179(48):
pubmed: 29208200
Epidemiol Infect. 2014 Dec;142(12):2461-70
pubmed: 24831052
Hum Vaccin Immunother. 2017 May 4;13(5):1182-1189
pubmed: 28140784
Euro Surveill. 2017 Jun 8;22(23):
pubmed: 28661395
Rev Chilena Infectol. 2015 Apr;32(2):242-3
pubmed: 26065462
Vaccine. 2018 Jun 18;36(26):3876-3881
pubmed: 29699791
PLoS One. 2013 Jun 11;8(6):e66006
pubmed: 23776590
South Med J. 1980 Mar;73(3):395-6
pubmed: 6767281
Med Clin (Barc). 2016 Sep 2;147(5):225-226
pubmed: 27207241
Clin Infect Dis. 2003 Dec 15;37(12):1639-42
pubmed: 14689345
MMWR Morb Mortal Wkly Rep. 2001 Mar 30;50(12):221-2
pubmed: 11300626
Br J Nurs. 2016 May 26-Jun 8;25(10):534
pubmed: 27231734
J Infect Chemother. 2018 May;24(5):398-400
pubmed: 29373268
Clin Infect Dis. 2015 Feb 15;60(4):578-85
pubmed: 25389259
Med Mal Infect. 2010 Jun;40(6):366-7
pubmed: 19959310
Euro Surveill. 2016;21(12):
pubmed: 27035055
J Infect. 2015 Nov;71(5):544-52
pubmed: 26226598
Euro Surveill. 2018 Apr;23(16):
pubmed: 29692317
Rev Chilena Infectol. 2013 Aug;30(4):350-60
pubmed: 24248103
Afr J Med Med Sci. 1990 Mar;19(1):1-3
pubmed: 2109513

Auteurs

C Stinson (C)

Medical Development & Scientific and Clinical Affairs, Pfizer Inc, 500 Arcola Rd, Collegeville, PA19426, USA.

C Burman (C)

Medical Development & Scientific and Clinical Affairs, Pfizer Inc, 500 Arcola Rd, Collegeville, PA19426, USA.

J Presa (J)

Medical and Scientific Affairs, Pfizer Inc, 500 Arcola Road, Collegeville, PA19426, USA.

M Abalos (M)

Medical Affairs, Pfizer SRL, Colectora Panamericana 1804, 1° piso, Sector "B" lado Sur, B1607EEV, Villa Adelina, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH